Navigation Links
Medisafe 1 Technologies to Start the $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share

JERUSALEM, Israel, February 13, 2012 /PRNewswire/ --

Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company plans to start the implementation of the share buyback at the beginning of the forthcoming month of March 2012

Under the program approved by the BOD, Medisafe 1 Technologies is authorized to repurchase up to 10 million of its outstanding shares of common stock during the next 12 months at a price up to $0.10 per share on the open market or by conducting privately negotiated transactions depending on current market conditions and other factors.

"Medisafe 1 Technologies continues to progress in our efforts to bring further added value to our shareholders," said Jacob Elhadad, CEO of Medisafe 1 Technologies Corp. "The repurchase of shares will enable us to acquire additional technologies that augment our existing commercial product line and we will updating our shareholders in the forthcoming weeks of new and exciting news in regards to further acquisitions."

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at

Contact: Jacob Elhadad CEO +972-524440000

SOURCE Medisafe 1 Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. The Israeli Governments Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology
2. Medisafe 1 Technologies Announces 1-5 Stock Dividend
3. Spherix to Present at the LHA Life Sciences & Medical Technologies Virtual Conference on February 16
4. BioStorage Technologies to Host Global Sample Management Workshop at Partnerships in Clinical Trials
5. UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt
6. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
7. FirstMark to Exhibit at Cardiovascular Research Technologies (CRT) 2012 Conference
8. Cell Therapy - Technologies, Markets and Companies
9. Life Technologies to Present at Upcoming Investment Conferences in February
10. Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China
11. Life Technologies Announces Redemption of 1.5% Convertible Senior Notes Due 2024
Post Your Comments:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality ... Several trends in analytical testing are being attributed to new regulatory requirements for ...
(Date:10/11/2017)... ... October 11, 2017 , ... Personal eye wash is a basic first aid supply ... a time. So which eye do you rinse first if a dangerous substance enters both ... Duo Eye Wash with its unique dual eye piece. , “Whether its dirt and ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/10/2017)... SAN DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... website as part of its corporate rebranding initiative announced today. The bold new ... broaden its reach, as the company moves into a significant growth period. , It ...
Breaking Biology Technology:
(Date:10/4/2017)... a global clinical research organization (CRO), announces the launch of Shadow, ... 2017. Shadow is designed to assist medical writers and biometrics teams ... European Medicines Agency (EMA) in meeting the requirements for de-identifying clinical ... ... Tom ...
(Date:6/23/2017)... N.Y. and ITHACA, N.Y. ... ) and Cornell University, a leader in dairy research, ... with bioinformatics designed to help reduce the chances that ... With the onset of this dairy project, Cornell University ... Consortium for Sequencing the Food Supply Chain, a food ...
(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
Breaking Biology News(10 mins):